Clinical trials: Aromatase Inhibitors
Breast Cancer
Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer
RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function.
- Trial name
- NCT00719966
- Testing
- anastrozole, exemestane, letrozole
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Mayo Clinic
Breast Cancer
Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA).
- Trial name
- NCT06654570
- Testing
- Intravaginal estrogen during adjuvant letrozole
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Helsinki University Central Hospital
Operable Breast Neoplasms
Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
The hypothesis to be addressed in this randomized phase III trial is that 4 months of letrozole may be superior to surgery as primary therapy for early stage hormone receptor positive breast cancer in postmenopausal women…
- Trial name
- REAL (NCT00908531)
- Testing
- letrozole (Femara)
- Where
- 9 sites in Denmark
- Volunteers
- 123 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Breast Cancer Patients Treated With Aromatase Inhibitors
Exploratory Study Therapeutic Fasting Reduce Physical Limitations, Quality of Life During Aromatase Inhibitor Therapy
In this explorative study, the feasibility of therapeutic fasting to reduce limitations in physical well-being and quality of life of patients undergoing endocrine therapy with aromatase inhibitors will be investigated.
- Trial name
- FREE-AI (NCT06172088)
- Testing
- Fasting
- Where
- 2 sites in Germany
- Volunteers
- 54 people
- Sponsor
- University Hospital Tuebingen
Vaginal Atrophy
Evaluation of VagiVital® for Treatment of Vaginal Atrophy
An open study to evaluate the ability of VagiVital in reducing the severity of moderate to severe symptoms of vaginal atrophy for women under treatment on adjuvant aromatase inhibitor therapy.
- Trial name
- NCT03998722
- Testing
- Vagivital
- Where
- Sweden
- Volunteers
- 31 people
- Sponsor
- PepTonic Medical AB
Breast Cancer, Recurrent Breast Cancer
Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain
RATIONALE: Acupuncture may help relieve moderate or severe joint pain caused by aromatase inhibitors. PURPOSE: This randomized phase II trial is studying acupuncture in treating women with stage I, stage II, or stage III breast…
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01013337
- Testing
- acupuncture therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Uterine Adenomyosis, Recurrent Implantation Failure
Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis
With this study the investigators want to test which is the best medical treatment for symptomatic adenomyosis affecting women undergoing IVF and with previous implantation failure, between Aromatase inhibitor plus GnRH analog…
- Conditions
- Uterine Adenomyosis, Recurrent Implantation Failure, Menstrual Pain
- Trial name
- NCT03421639
- Testing
- GnRH analog (11.25mg Leuprolide acetate), Aromatase inhibitor and GnRH analog, Aromatase and GnRH analog (11.25mg Leuprolide acetate)
- Where
- 3 sites in Albania, Bulgaria and 1 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Centre for Endocrinology and Reproductive Medicine, Italy
HER2-Positive Breast Carcinoma
Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.
- Trial name
- NCT06557057
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Hormone Receptor-Positive Breast Cancer
Estradiol Levels According to Body Mass Index in Premenopausal Patients With Breast Cancer
his prospective observational study will evaluate whether body mass index (BMI) is associated with serum estradiol levels in premenopausal women with hormone receptor-positive breast cancer.
- Trial name
- SIMPEC-E2 (NCT07833501)
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- D'Or Institute for Research and Education
UTERINE LEIOMYOMA
Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy
The investigators aimed to assess if use of aromatase inhibitors could decrease volume of uterine leiomyoma and cause same percentage of adverse effects during its use compared to GnRH analogs.
- Trial name
- NCT01280045
- Testing
- VAGINAL HYSTERECTOMY
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Breast Cancer
Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer
The purpose of this research study is to study the effects of using aromatase inhibitor (AI) therapy intermittently on participants with breast cancer. AIs are a class of drugs used to treat breast cancer in postmenopausal women.
- Trial name
- NCT00549822
- Testing
- Letrozole
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Polyostotic Fibrous Dysplasia, Precocious Puberty
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty
The normal changes of puberty, such as breast enlargement, pubic hair and menstrual periods, usually begin between the ages of 9 and 15 in response to hormones produced in the body.
- Trial name
- NCT00001181
- Testing
- Testolactone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), Breast Cancer
Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome
This is a pilot trial to evaluate for blood and imaging biomarkers in patients with breast cancer scheduled to start adjuvant hormonal therapy.
- Trial name
- NCT03665077
- Testing
- Initial blood draw, Initial SWE ultrasound, Blood draw at three months
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Arizona
Breast Cancer, Pain
S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer
RATIONALE: Acupuncture may help relieve joint pain. PURPOSE: This randomized phase III trial studies acupuncture to see how well it works compared to sham acupuncture or waitlist in treating patients with joint pain related to…
- Trial name
- NCT01535066
- Testing
- acupuncture therapy
- Where
- 47 sites in United States
- Volunteers
- 226 people
- Sponsor
- SWOG Cancer Research Network
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain
This clinical trial evaluates how well tonation breathing techniques (use of a breathing and tonation [creating sounds]) works to ease pain joint and/or muscle pain in patients with stage I-III breast cancer and currently take an…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT05412953
- Testing
- Questionnaire Administration, Tonation Breathing Technique
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Cancer
FES-PET for Patients Treated on NCI Protocol 8762
A significant number of all invasive breast cancers are hormone sensitive and may be candidates for treatment with hormonal therapy.
- Trial name
- NCT01714128
- Testing
- Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))
- Where
- United States
- Sponsor
- Washington University School of Medicine
Breast Cancer
Altering Lipids for Tolerance of Aromatase Inhibitor Therapy
Aromatase inhibitor medications have been approved by the U.S Food and Drug Administration (FDA) for treatment of hormone receptor positive breast cancer.
- Trial name
- ALTA (NCT04268134)
- Testing
- Omega-3 fatty acid supplement
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoadjuvant Therapy
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
The investigators designed this study to investigate the effect of aromatase inhibitors (AI) plus chemotherapy versus chemotherapy as neoadjuvant treatment in postmenopausal hormone receptor-positive breast cancer.
- Trial name
- ACCN (NCT02769104)
- Testing
- Letrozole (Aromatase Inhibitors), AC*4-T*4
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Female, HER2-positive Breast Cancer
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
This study is a single-arm, open-label, phase II study, comparing the efficacy and safety of pyrotinib plus trastuzumab and aromatase inhibitors, in the treatment of HR (hormone receptor)+/HER2 (human epidermal growth factor…
- Conditions
- Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer
- Trial name
- NCT04088110
- Testing
- Pyrotinib, Trastuzumab, Aromatase Inhibitors
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Fuzhou General Hospital